

1 **Peripheral blood leukocyte signatures as biomarkers in relapsed ovarian cancer**  
2 **patients receiving combined anti-CD73/anti-PD-L1 immunotherapy in Arm A of the**  
3 **NSGO-OV-UMB1/ENGOT-OV30 trial**

4  
5 Luka Tandarić<sup>1,2</sup>, Annika Auranen<sup>3,4</sup>, Katrin Kleinmanns<sup>1</sup>, René DePont Christensen<sup>5</sup>, Liv  
6 Cecilie Vestrheim Thomsen<sup>1,2,6</sup>, Cara Ellen Wogsland<sup>1,7</sup>, Emmet McCormack<sup>1,8,9</sup>,  
7 Johanna Mäenpää<sup>3,4,10</sup>, Kristine Madsen<sup>5</sup>, Karen Stampe Petersson<sup>5</sup>, Mansoor Raza  
8 Mirza<sup>5,11</sup>, Line Bjørge<sup>\*,1,2</sup>

9  
10 <sup>1</sup>Centre for Cancer Biomarkers CCBio, Department of Clinical Science, University of  
11 Bergen, Bergen, Norway

12 <sup>2</sup>Department of Obstetrics and Gynecology, Haukeland University Hospital, Bergen,  
13 Norway

14 <sup>3</sup>Department of Obstetrics and Gynecology and Tays Cancer Centre, Tampere University  
15 Hospital, Tampere, Finland

16 <sup>4</sup>Nordic Society of Gynaecological Oncology – Clinical Trial Unit (NSGO-CTU), Tampere,  
17 Finland

18 <sup>5</sup>Nordic Society of Gynaecological Oncology – Clinical Trial Unit (NSGO-CTU),  
19 Copenhagen, Denmark

20 <sup>6</sup>Department of Health Registry Research and Development, Norwegian Institute of  
21 Public Health, Oslo, Norway

22 <sup>7</sup>Kinn Therapeutics AS, Bergen, Norway

23 <sup>8</sup>Centre for Pharmacy, Department of Clinical Science, University of Bergen, Bergen,  
24 Norway

25 <sup>9</sup>Department of Internal Medicine, Hematology Section, Haukeland University Hospital,  
26 Bergen, Norway

27 <sup>10</sup>Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland

28 <sup>11</sup>Department of Oncology, Rigshospitalet, Copenhagen University Hospital,  
29 Copenhagen, Denmark

30 \*Corresponding author

31

32

33

34

35

36

37

38

39

40

41

42

43 **ABSTRACT**

44 **Background:** Clinical trials of immune checkpoint inhibitors in epithelial ovarian cancer  
45 (EOC) have not shown clear survival benefit, likely due to the complex  
46 immunosuppressive mechanisms of the EOC tumor microenvironment. Still, certain  
47 patients experience long-term treatment benefit. However, we lack reliable biomarkers  
48 for distinguishing dominant immunosuppressive mechanisms and for identifying patients  
49 with EOC who are responsive to immunotherapy. The present high-dimensional single-  
50 cell study analyzed patients with relapsed EOC enrolled in arm A of the NSGO-OV-  
51 UMB1/ENGOT-OV30 trial, wherein the patients underwent combination oleclumab (anti-  
52 CD73) and durvalumab (anti-PD-L1) immunotherapy. The objective of the study was the  
53 identification of blood-based immunophenotypic signatures conducive to the  
54 development of improved strategies for patient selection, response monitoring, and  
55 personalized targeting of immunosuppressive mechanisms.

56 **Methods:** A 40-marker suspension mass cytometry panel was utilized for  
57 comprehensive phenotypic and functional characterization of longitudinally sampled  
58 peripheral blood leukocytes from patients. Artificial neural network-based unsupervised  
59 clustering and manual metacluster curation were used to identify leukocyte subsets for  
60 differential discovery and correlation analyses.

61 **Results:** At baseline, short-term and long-term survivors differed with regard to the  
62 relative abundances of total peripheral blood mononuclear cells (PBMCs). We observed  
63 a significant increase in CD14<sup>+</sup>CD16<sup>-</sup> myeloid cells during treatment, initially driven by  
64 classical monocyte proliferation and subsequently driven by the expansion of monocytic  
65 myeloid-derived suppressor cells (M-MDSCs). This M-MDSC expansion occurred only in

66 patients with shorter progression-free survival, who also showed a continuous decrease  
67 in central memory T-cell abundances after baseline. Throughout treatment, we observed  
68 upregulation of PD-L1 expression on most T-cell subsets in all patients. Higher  
69 expression of CD73 and IDO1 on select leukocyte subsets at baseline was significantly  
70 positively correlated with longer progression-free survival.

71 **Conclusions:** Our study delineates the phenotypic and functional alterations in  
72 peripheral blood leukocytes occurring during combination oleclumab/durvalumab  
73 immunotherapy in patients with relapsed EOC. We propose a set of biomarkers with  
74 potential for treatment personalization and response monitoring: relative abundances of  
75 PBMCs at baseline, relative abundances of M-MDSCs and central memory T cells  
76 during treatment; PD-L1 expression levels over time; and baseline expression of CD73  
77 and IDO1 on specific leukocyte subsets. However, validation of these biomarkers  
78 through larger-scale studies is required.

79

## 80 **KEY MESSAGES**

### 81 **WHAT IS ALREADY KNOWN ON THIS TOPIC**

82 Despite promising preclinical results and moderate efficacy in lung cancer, combination  
83 anti-CD73/anti-PD-L1 immunotherapy in relapsed epithelial ovarian cancer (EOC) has  
84 shown only modest response rates, consistent with other EOC immunotherapy trials.  
85 Durable clinical benefit remains rare, and there are currently no biomarkers available for  
86 the effective selection of EOC patients for personalized immunotherapy and for the  
87 characterization of sustained responses.

88 **WHAT THIS STUDY ADDS**

89 This study demonstrates that, at baseline of combination anti-CD73/anti-PD-L1  
90 treatment, EOC patients with higher relative abundances of peripheral blood  
91 mononuclear cells (PBMCs) and elevated expression of CD73 and IDO1 on certain  
92 PBMC subsets may experience greater overall survival and progression-free survival  
93 benefit, respectively. Additionally, patients with faster disease progression exhibited a  
94 shift in CD14<sup>+</sup>CD16<sup>-</sup> myeloid cells towards a more immunosuppressive phenotype and  
95 had lower abundances of central memory T cells over time compared to patients with  
96 slower progression, while PD-L1 expression increased significantly over time on T cells  
97 of all patients, regardless of the rate of disease progression.

98

99 **HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY**

100 While further clinical validation is required, we propose blood-based biomarkers for  
101 predicting and monitoring responses to immunotherapy in EOC, aiming to guide future  
102 research on immunotherapy resistance mechanisms and treatment personalization, with  
103 a focus on specific peripheral leukocyte subsets.

104

105 **KEYWORDS**

106 Humans; Epithelial ovarian cancer; Immunotherapy; Immune checkpoint inhibitor;  
107 durvalumab; oleclumab; Mass Cytometry; Myeloid-derived suppressor cells; Leukocytes,  
108 Mononuclear; Biomarkers

## 109 INTRODUCTION

110 Epithelial ovarian cancer (EOC) is predominantly diagnosed at an advanced stage. For  
111 the past few decades, surgical cytoreduction followed by carboplatin-paclitaxel  
112 chemotherapy has been the default approach to treating EOC [1]. Recently, the clinical  
113 implementation of poly(ADP-ribose) polymerase inhibitors (PARPi's) and the anti-  
114 angiogenesis agent bevacizumab as maintenance therapy has significantly improved  
115 survival [2]. However, despite most patients initially responding to primary treatment,  
116 70%-80% of the responders eventually experience relapse [3]. Although multiple  
117 therapeutics are used to treat recurrent disease, the treatment intent shifts from curative  
118 to palliative. Drug resistance and the dearth of effective post-relapse treatment options  
119 have resulted in the long-term survival rates remaining low [4] and highlighted the need  
120 for novel treatment modalities.

121  
122 Immunotherapy, particularly the clinical implementation of immune checkpoint inhibitors  
123 (ICIs), has improved the outcomes of several cancers by disrupting tumor immune  
124 evasion mechanisms, mainly the induction of T-cell exhaustion [5]. Seminal studies by  
125 Zhang et al. [6] and Curiel et al. [7], correlating treatment response and survival with the  
126 presence, position, and phenotypes of tumor-infiltrating lymphocytes in EOC, have  
127 indicated rationale for applying immunotherapy in EOC as well. Although numerous trials  
128 on immunotherapeutic regimens in EOC have been conducted, including studies  
129 incorporating patient pre-selection strategies based on predictive biomarkers, such as  
130 PD-L1 [8], none have shown sufficient efficacy to be considered clinically viable [9].  
131 Immunotherapy has failed to achieve potency in EOC on account of multiple

132 immunoinhibitory mechanisms simultaneously active in its tumor microenvironment  
133 (TME). This facilitates a high degree of immunosuppression, unsurmountable by  
134 immunotherapeutics delivered either as a monotherapy or in combination with  
135 chemotherapeutics [10]. In preclinical studies on EOC, combination immunotherapy  
136 regimens have resulted in notable increases in antitumor efficacy over single-agent  
137 immunotherapeutics, predominantly by inhibition of PD-1/PD-L1 interaction alongside  
138 simultaneous activation of an immunostimulatory receptor on T cells [11].

139  
140 Building off of promising preclinical results of combination immunotherapies in murine  
141 models of solid cancers, which had shown significant synergistic effects in terms of  
142 tumor reduction and survival improvement, as well as elevated abundance and anti-  
143 tumor activity of CD8<sup>+</sup> T cells, compared to the corresponding monotherapies [12-14],  
144 the non-randomized phase II trial NSGO-OV-UMB1/ENGOT-OV30 was designed as a  
145 three-arm umbrella trial for testing the clinical efficacy of several novel combinations of  
146 immunotherapeutics in patients with relapsed EOC [15]. The treatment in arm A  
147 comprised oleclumab and durvalumab - human monoclonal IgG1 antibodies that target  
148 and inhibit CD73 and PD-L1, respectively. CD73, an adenosine-generating extracellular  
149 enzyme present on most normal tissues [16], is overexpressed in most cancers [17] and  
150 associated with poor prognosis in EOC [18]. Binding of adenosine to A2A receptors on  
151 antigen-activated T cells results in activation blockage and exhaustion [19]. Accordingly,  
152 inhibition of the CD73/A2A receptor axis is considered an effective means of re-  
153 invigorating anti-tumor immunity [20]. Furthermore, simultaneous inhibition of CD73 and  
154 the PD-1/PD-L1 interaction in preclinical *in vitro* and *in vivo* human cell line models was  
155 shown to have a synergistic anti-tumor effect compared to the individual inhibition of

156 either [21]. Based on these results, the oleclumab/durvalumab combination was  
157 approved for testing in a phase II clinical trial setting [15]. While it demonstrated only  
158 marginal clinical efficacy in a relapsed EOC cohort, a number of patients exhibited  
159 prolonged survival.

160  
161 This translational study presents the results of the high-dimensional single-cell  
162 suspension cytometry by time-of-flight (CyTOF) analysis of blood samples collected from  
163 trial cohort A prior to treatment and at regular intervals during treatment. The aim was  
164 the elucidation of clinically actionable phenotypic signatures of the response of relapsed  
165 EOC to oleclumab/durvalumab immunotherapy. We identified potential leukocyte-based  
166 predictive, prognostic, and response biomarkers for the purposes of improved patient  
167 selection, preemptive detection of cancer progression, and portrayal of *in vivo* drug  
168 activity, respectively.

169

## 170 **METHODS**

### 171 **Patient cohort and samples**

172 In the international NSGO-OV-UMB1/ENGOT-OV-30 umbrella trial, 25 immunotherapy-  
173 naïve patients with relapsed EOC who had CD73-positive archival tumor samples were  
174 included in arm A and intravenously administered 3000 mg oleclumab and 1500 mg  
175 durvalumab every two and four weeks, respectively (figure 1A). The primary endpoint  
176 was response evaluation (disease control rate) at the 16-week timepoint. Peripheral  
177 blood samples for single-cell suspension CyTOF were collected in 10 mL EDTA  
178 Vacutainer tubes (Becton Dickinson, REF 367525) at baseline (pre-treatment), at  
179 minimum every two 28-day cycles, and at end of trial or at disease progression. Within



180 one hour of collection, samples were processed using BD Phosflow Lyse/Fix buffer  
181 (Becton Dickinson, REF 558049) and frozen at -80°C (figure 1B,C) (protocol described  
182 in the online supplemental appendix). Samples were stored in the biobank of Haukeland  
183 University Hospital, Bergen, Norway.

184

### 185 **Mass cytometry panel development**

186 A 40-marker antibody panel (online supplemental table S1) encompassing the entire  
187 human peripheral blood leukocyte repertoire was designed and developed in-house for  
188 in-depth single-cell analysis of the leukocyte samples. As the aim of  
189 oleclumab/durvalumab immunotherapy was the reinvigoration of T cells from an  
190 exhausted state, a central objective of the panel was ascertainment of information about  
191 T-cell states before and during treatment. Given that myeloid cells in the peripheral  
192 blood have been observed to significantly influence the outcome of immunotherapy of  
193 solid cancers [22], as well as have a crucial influence on treatment outcome upon  
194 settlement into the TME of EOC [23], another objective of the panel was the  
195 characterization of the myeloid cells in the samples.

196 For antibody clones not commercially available in a pre-metal-conjugated format, 100 µg  
197 of purified, carrier-protein-free antibody was conjugated in-house to cadmium- or  
198 lanthanide-loaded polymers using Maxpar MCP9 or X8 antibody labeling kits,  
199 respectively, according to the manufacturer's protocol (Standard BioTools).

200 Antibodies were titrated on leukocytes from whole blood collected from healthy female  
201 donors and processed using the Lyse/Fix buffer. Titration of lineage and cell state

202 markers was performed on unstimulated leukocytes, and peripheral blood mononuclear  
203 cells (PBMCs) stimulated *in vitro* by interleukin-2 (IL-2) (Sigma, Cat.No. I2644) and  
204 phytohemagglutinin-P (PHA-P) (Sigma, Cat.No. 61764), respectively, according to the  
205 protocol in the online supplemental appendix. To ensure consistency, identical sample  
206 processing and staining protocols were maintained for the titration samples and clinical  
207 samples. The optimal concentration of Cell-ID Intercalator-Ir (Standard BioTools, Cat.No.  
208 201192B) for the identification of nucleated cells was determined to be 250 nM by  
209 titration. The panel was validated for use on the CyTOF XT mass cytometer (Standard  
210 BioTools).

211

## 212 **Sample staining and data acquisition**

213 To facilitate uniform staining, batches containing up to 20 samples were designed,  
214 wherein a unique palladium-based tag was assigned to each sample. For batch effect  
215 correction, each barcoded batch contained two different anchor samples consisting of  
216 Lyse/Fix-treated healthy donor leukocytes, one of which had an admixture of PHA-P/IL-  
217 2-treated healthy donor PBMCs to enable batch correction of activation/exhaustion  
218 markers. Frozen fixed leukocyte samples were thawed and treated with 0.25 mg/mL  
219 DNase I (Sigma, Cat.No. DN25) dissolved in Dulbecco's phosphate-buffered saline  
220 containing  $\text{Ca}^{2+}$  and  $\text{Mg}^{2+}$  (Sigma, Cat.No. D8662) (henceforth referred to as "DNase").  
221 Cells were counted, and a maximum of  $3.5 \times 10^6$  cells from each sample were tagged  
222 using a palladium-based barcoding method according to the manufacturer's protocol  
223 (Standard BioTools, Cat.No. 201060). Barcoding reagents were washed away, and all  
224 cells within a batch were pooled, counted, and frozen at  $-80^\circ\text{C}$ .

225 To maintain consistency in the composition of staining antibody mixes across sample  
226 batches, two mixes of antibodies, targeting either surface or intracellular markers, were  
227 pre-made in quantities large enough to stain the full set of samples, aliquoted, and  
228 stored at -80°C. Comparative testing of frozen versus freshly-made antibody mixes on  
229 Lyse/Fix-treated healthy donor leukocytes demonstrated that freezing did not affect the  
230 effectiveness or specificity of the panel antibodies.

231 For staining, barcoded sample mixes were thawed and counted. Cells were then  
232 incubated in MaxPar Cell Staining Buffer (CSB) (Standard BioTools, Cat.No. 201068)  
233 containing human FcR Blocking Reagent (Miltenyi Biotec, Cat.No. 130-059-901), and  
234 heparin (Ratiopharm, Reg.No. 5394.00.00) to prevent non-specific antibody binding.  
235 Aliquots of the antibody mix for staining cell surface proteins were thawed and added to  
236 the cells at  $3 \times 10^6$  cells per 100  $\mu$ L of staining volume. After incubating for 45 minutes at  
237 room temperature (RT), superfluous antibody was washed away with MaxPar CSB, then  
238 with MaxPar phosphate-buffered saline (PBS) (Standard BioTools, Cat.No. 201058),  
239 after which cells were permeabilized by a 10-minute incubation in pure methanol  
240 (Sigma, Cat.No. 32213) at -20°C. The methanol was washed away with MaxPar PBS,  
241 followed by MaxPar CSB. Aliquots of the antibody mix for targeting intracellular proteins  
242 were thawed and applied to the permeabilized cells for 30 minutes at RT, at a  
243 concentration of  $3 \times 10^6$  cells per 100  $\mu$ L of staining volume. For DNA staining, washed  
244 cells were incubated with iridium intercalator diluted in MaxPar PBS containing 4% V/V  
245 formaldehyde for 20 min at RT. The cells were washed, resuspended in a 10% V/V  
246 solution of dimethyl-sulfoxide (Sigma, Cat.No. W387520) in fetal bovine serum (Sigma,  
247 Cat.No. F7524) and frozen at -80°C.

248 For data acquisition, fully stained cells were thawed, washed using MaxPar CSB, and  
249 incubated in DNase. Cells were then washed and pelleted in MaxPar Cell Acquisition  
250 Solution (Standard BioTools, Cat.No 201240), kept on ice until data acquisition, and  
251 acquired in MaxPar Cell Acquisition Solution Plus (Standard BioTools, Cat.No. 201244).  
252 High-dimensional data from three barcoded batches was acquired on a CyTOF XT mass  
253 cytometer at ~400 events per second, with EQ Six-Element Calibration Beads (Standard  
254 BioTools, Cat.No. 201245) present in the suspension at a 1:10 dilution (detailed  
255 barcoding and staining methodologies provided in the online supplemental appendix).

256

## 257 **Data pre-processing**

258 Bead-based longitudinal signal intensity normalization was done automatically by the  
259 CyTOF XT software upon data acquisition. Events were de-barcoded using the MATLAB  
260 Compiler Runtime (R2013a(8.1)) implementation of The Single Cell Debarcoder by  
261 Zunder et al. [24]. De-barcoded events were uploaded to Cytobank (Beckman Coulter  
262 Inc.), where irregular events were removed by manual gating (online supplemental figure  
263 S1). The resulting single-cell events were batch corrected with the R-based GUI  
264 implementation of CytobatchAdjust by Schuyler et al. (v0.0.0.9001) [25], using the  
265 composite anchor sample of each batch. Batch correction effectiveness was assessed  
266 by analyzing the corrected data of the alternate anchor sample.

267

## 268 **Clustering and differential analyses**

269 Unsupervised clustering, dimensionality reduction, manually curated metaclustering, and  
270 differential analyses were performed using the “flowSOM” [26], “umap” [27],  
271 “CATALYST” [28], and “diffcyt” [29] R packages, respectively.

272 Total leukocyte data from all patient samples was first clustered into a 64-cluster (8×8)  
273 self-organizing map (SOM) and manually metaclustered into granulocyte, PBMC, and  
274 debris subsets based on the expression of 13 markers (figure 2A). The assignment of  
275 cell identity was rigorously quality checked using biaxial plots, heatmaps, UMAPs, and  
276 hierarchical clustering of clusters. The PBMC subset was further sub-clustered into a  
277 256-cluster (16×16) SOM and manually grouped into 24 subsets corresponding to  
278 widely established PBMC types using 22 markers (figure 2B). Subset assignment was  
279 validated in the same manner as that for total leukocytes.

280

## 281 **Statistical analyses**

282 Differential subset abundance and cell state marker expression between clinical sample  
283 groups, stratified by length of survival, duration of progression-free survival (PFS), or  
284 sampling timepoint, were analyzed using the edgeR and limma functions of the diffcyt R  
285 package, respectively. Multiple hypothesis testing correction was conducted using the  
286 Benjamini-Hochberg method, giving adjusted p-values ( $p_{adj}$ ).

287 To identify potential predictive biomarkers among baseline leukocyte characteristics, the  
288 relationships between PFS duration, and either relative cell subset abundances or state  
289 marker expression medians for each cell subset were analyzed using GraphPad Prism  
290 (v10.2.0, GraphPad Software). Given that patients in the short-term survivor group had

291 died prior to the first tumor evaluation timepoint, this analysis was restricted to the seven  
292 patients in the long-term survivor group. According to the results of Shapiro-Wilk  
293 normality testing ( $\alpha=0.05$ ), either a Pearson or Spearman correlation test was  
294 performed for each marker-subset combination (dataset) alongside simple linear  
295 regression to assess the relationship between PFS duration and relative abundances or  
296 expression medians. The p-values in the correlation analyses were not corrected for  
297 multiple hypothesis testing due to the small size of datasets ( $n=7$ ) and the discovery-  
298 driven nature of this study. To maintain robustness, we considered significant  
299 correlations with an absolute correlation coefficient of at least 0.5 and an R-squared  
300 value of at least 0.75 as meaningful.

301

## 302 **RESULTS**

### 303 **Study cohort demographics**

304 In this retrospective translational study, we analyzed total leukocytes longitudinally  
305 sampled from patients with relapsed EOC undergoing combination  
306 oleclumab/durvalumab immunotherapy (figure 1A) with the aim of identifying predictive,  
307 prognostic, and response biomarkers for the administered treatment. Out of the 25-  
308 patient trial cohort, 16 patients were not eligible for this study due to samples either  
309 missing or being of inadequate quality (figure 1B). Therefore, the data in this study  
310 stems from 36 leukocyte samples of nine patients (figure 1C). Nonetheless, our study  
311 cohort is highly representative of the clinical trial cohort [15], as the patient age range  
312 and distributions of FIGO stage, ECOG status, and clinical response are similar (table

313 1). In contrast to the patients in the clinical trial, the majority of the patients included in  
314 this study had undergone more extensive treatment prior to inclusion.

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332 **Table 1** Characteristics of the included patients.

Characteristic	No. of patients (n=9)
Age, years (%)	
Median (range)	66 (47-74)
40-49	1 (11.1)
50-59	1 (11.1)
60-69	3 (33.3)
≥70	4 (44.4)
FIGO stage at initial diagnosis (%)	
I	1 (11.1)
II	0 (0.0)
III	3 (33.3)
IV-A	4 (44.4)
IV-B	1 (11.1)
ECOG PS at baseline (%)	
0	3 (33.3)
1	6 (66.7)
Prior treatment lines (%)	
2	3 (33.3)
≥3	6 (66.7)
Treatment cycles received* (%)	
Median (range)	6 (1-15)
≤4	4 (44.4)
>4	5 (55.6)
Time to progression (weeks) (%)	
≤16	3 (33.3)
>16	4 (44.4)
N/A**	2 (22.2)
Best clinical response (%)	
CR	0 (0.0)
PR	1 (11.1)
SD	5 (55.6)
PD	1 (11.1)
N/A**	2 (22.2)

333 \*One cycle corresponds to four weeks of treatment.

334 \*\* Patients passed away prior to the first post-baseline tumor evaluation.

335 FIGO - International Federation of Gynecology and Obstetrics

336 ECOG PS - Eastern Cooperative Oncology Group performance status

337



## 338 **CytoTOF analysis enabled in-depth characterization of patients' leukocyte profiles**

339 We utilized single-cell suspension CyTOF for high-dimensional phenotypic profiling of  
340 patient leukocytes. Approximately 21 million total events were acquired from the 36  
341 leukocyte samples. After quality controls, single-cell data of about 19 million leukocytes  
342 remained for further analysis. After batch correction, unsupervised clustering using  
343 FlowSOM and manual metaclustering of the total leukocytes produced three leukocyte  
344 subsets - granulocytes, PBMCs, and debris (figure 2A). To achieve the intended  
345 analytical depth, the same clustering and metaclustering procedures were applied in  
346 higher resolution to the PBMCs, resulting in the clear delineation of 24 PBMC subsets  
347 (figure 2B). The robustness of the PBMC (meta)clustering was confirmed by using the  
348 UMAP dimensionality reduction algorithm on an aggregated dataset comprising 10,000  
349 PBMCs from each of the 36 samples (figure 2C).

350 All PBMC subtypes, except for the rarest populations (plasmablasts, CD141<sup>+</sup> myeloid  
351 dendritic cells, and CD4<sup>+</sup>CD8<sup>+</sup> T cells), were detected in all samples (figure 2D, online  
352 supplemental table S2). Inspection of the complete dataset revealed that each patient's  
353 leukocyte profile remained largely consistent over time, but inter-patient heterogeneity  
354 was markedly more pronounced (figure 2D). Nevertheless, certain trends in  
355 compositional changes of leukocyte profiles over time were observed, such as the  
356 expansion of myeloid cells at the cost of overall T-cell proportions in nearly all patients.  
357 To determine the significance of these observations for biomarker discovery, we  
358 performed differential analyses of leukocyte composition and cell state marker  
359 expression.

360

361 **Long-term survivors exhibit larger abundances of PBMCs at baseline**

362 To identify clinically relevant predictive biomarkers, patients were first stratified into  
363 short-term survivors ( $\leq 16$  weeks,  $n=2$ ) and long-term survivors ( $>16$  weeks,  $n=7$ ). We  
364 observed that long-term survivors had, on average, significantly higher relative  
365 abundance of total PBMCs at baseline ( $p_{\text{adj}}=0.0279$ ) (figure 3A,B). No significant  
366 differences were observed in the relative abundances of other cell subsets between the  
367 groups at baseline. As the short-term survivors provided only baseline samples, we  
368 could not compare other timepoints between the groups.

369  
370 **Oleclumab/durvalumab treatment was accompanied by significant CD14<sup>+</sup>CD16<sup>-</sup>**  
371 **myeloid cell expansion**

372 To ensure consistency and sufficient sample size for adequate statistical power when  
373 analyzing longitudinal changes, we evaluated only the samples from long-term survivors  
374 taken at baseline ( $n=7$ ) and after two ( $n=7$ ) and four treatment cycles ( $n=7$ ). Compared  
375 to baseline, the average frequency of classical monocytes (CD14<sup>+</sup>CD16<sup>-</sup>HLA-DR<sup>+/hi</sup>) in  
376 the peripheral blood samples significantly increased ( $p_{\text{adj}}=0.0248$ ) after two treatment  
377 cycles and remained elevated even after four treatment cycles, although not significantly  
378 ( $p_{\text{adj}}=0.299$ ) (figure 3C, left panel). Although there were no significant differences in the  
379 relative abundances of monocytic myeloid-derived suppressor cells (M-MDSCs)  
380 (CD14<sup>+</sup>CD16<sup>-</sup>HLA-DR<sup>-/lo</sup>) over time when analyzed separately from classical monocytes  
381 (figure 3C, middle panel), removing the division between classical monocytes and M-  
382 MDSCs based on HLA-DR expression (online supplemental figure S2) revealed a

383 significant expansion of CD14<sup>+</sup>CD16<sup>-</sup> myeloid cells relative to baseline. This expansion  
384 was evident after two treatment cycles ( $p_{\text{adj}}=0.0165$ ) and persisted even after four  
385 treatment cycles ( $p_{\text{adj}}=0.0231$ ) (figure 3C, right panel). We visualized this progressive  
386 increase in abundance by using UMAP to generate density-colored projections of  
387 aggregate samples of PBMCs from each timepoint (figure 3D).

388  
389 **Myeloid MDSC expansion and central memory T-cell contraction are tied to**  
390 **progression onset**

391 All seven patients in the long-term survivor group experienced tumor progression and  
392 were subsequently categorized either as rapid progressors (n=3), who experienced  
393 disease progression within the first 16 weeks (four cycles) of treatment, or slow  
394 progressors (n=4), who had disease progression more than 16 weeks from the start of  
395 treatment. Differential abundance analyses showed significant expansion of the M-  
396 MDSC subset after four treatment cycles in the rapid progressors ( $p_{\text{adj}}=6.89\times 10^{-8}$ ) (figure  
397 3E, left panel), with no significant longitudinal changes in subset abundance occurring in  
398 the slow progressors (figure 3E, right panel). Furthermore, among rapid progressors, we  
399 observed a consistent decline, leading to a statistically significant contraction, of both  
400 CD4<sup>+</sup> ( $p_{\text{adj}}=0.0477$ ) and CD8<sup>+</sup> ( $p_{\text{adj}}=0.0477$ ) central memory (CD27<sup>+</sup>CD45RO<sup>+</sup>CD45RA<sup>-</sup>)  
401 T-cell ( $T_{\text{CM}}$ ) subsets after four treatment cycles (figure 3F, two left panels). This trend  
402 was not observed among the slow progressors (figure 3F, two right panels).

403 For five out of the seven long-term survivors, samples from before and after confirmation  
404 of progression were available. We noted a marked trend towards increased abundance

405 of M-MDSCs following progression (figure 3G); however, this did not reach statistical  
406 significance ( $p_{\text{adj}}=0.0537$ ).

407

408 **PD-L1 expression is upregulated on T cells during oleclumab/durvalumab**  
409 **treatment**

410 We subsequently performed differential analyses of cell state marker expression levels  
411 to investigate inter-group differences and longitudinal changes in the activation,  
412 exhaustion, or terminal differentiation of leukocytes, as well as in the activity of signaling  
413 pathways potentially influenced by inhibition of adenosinergic signaling [30]. Differential  
414 analyses of state marker expression levels between treatment timepoints and baseline  
415 in the long-term survivors revealed significant upregulation of PD-L1 expression across  
416 nearly all CD4<sup>+</sup> and CD8<sup>+</sup> T-cell subsets (figure 4). After two treatment cycles, PD-L1  
417 expression was significantly increased in all memory (CD45RO<sup>+</sup>) T-cell subsets and  
418 across all CD4<sup>+</sup> T-cell subsets, with the CD4<sup>+</sup> memory T cells showing the highest  
419 expression and largest increases (figure 4A - left panel; figure 4B). Following four  
420 treatment cycles, PD-L1 expression was significantly elevated compared to baseline in  
421 all T-cell subsets except the effector memory (CD27<sup>-</sup>CD45RO<sup>+</sup>CD45RA<sup>-</sup>) T-cell subsets  
422 (figure 4A - right panel; figure 4B). Notably, the lowest PD-L1 expression among the T-  
423 cell subsets was observed in the naive (CD27<sup>+</sup>CD45RO<sup>-</sup>CD45RA<sup>+</sup>) T-cell subsets (figure  
424 4B).

425 Comparisons of cell state marker expression between rapid and slow progressors, as  
426 well as between pre- and post-progression samples, did not reveal any significant

427 differences. Interestingly, no significant changes or trends were observed in the  
428 expression levels of markers associated with the adenosinergic signaling pathway  
429 (CD39, CD73, p-CREB, and p-S6) (data not shown).

430

431 **Baseline expression levels of CD73 and IDO1 positively correlate with the duration**  
432 **of progression-free survival**

433 To assess the impact of baseline abundances and phenotypes of peripheral blood  
434 leukocytes on PFS duration, we performed correlation analyses. No significant valid  
435 correlations were found between baseline subset abundances and PFS duration (figure  
436 5A) (online supplemental table S3). However, analyses of cell state marker expression  
437 revealed a strong positive correlation between baseline CD73 expression and PFS  
438 duration for most of the subsets comprising the patients' peripheral blood leukocyte  
439 repertoire (figure 5B). This correlation met the predefined robustness criteria in  
440 approximately one third of leukocyte subsets, predominantly encompassing the majority  
441 of the T-cell repertoire. Similarly, a strongly positive correlation with PFS duration was  
442 also observed for baseline IDO1 expression in a number of leukocyte subsets, although  
443 this correlation was significant in fewer subsets than observed for CD73 expression  
444 (figure 5C).

445

446 **DISCUSSION**

447 In this study, we report the findings from a high-dimensional single-cell analysis of blood  
448 samples from patients with relapsed EOC undergoing combination

449 oleclumab/durvalumab immunotherapy. To the best of our knowledge, this is the first  
450 study to employ single-cell CyTOF to assess blood-based biomarkers in patients with  
451 ovarian cancer undergoing immunotherapy. Through differential and correlative analyses  
452 of the abundances and phenotypes of peripheral blood leukocytes, we identified  
453 phenotypic signatures potentially indicative of disease progression and treatment  
454 efficacy. We show that patients with relapsed EOC who present with lower proportions of  
455 PBMCs in their peripheral blood leukocyte pool may derive inferior survival benefit from  
456 combined oleclumab/durvalumab treatment than patients with higher proportions of  
457 PBMCs. During treatment, we saw an increase in the relative abundance of circulating  
458 CD14<sup>+</sup>CD16<sup>-</sup> myeloid cells in the total patient cohort, along with a decrease in T<sub>CM</sub> cell  
459 proportions specific to rapidly progressing patients. We also observed a strong trend  
460 towards an increased relative abundance of circulating M-MDSCs at progression.  
461 Furthermore, we noted a significant increase in PD-L1 expression on circulating T cells  
462 during treatment. Finally, we demonstrate that PFS duration was positively correlated  
463 with pre-treatment expression levels of CD73 and IDO1 on several circulating leukocyte  
464 subsets.

465 In our study cohort, long-term survivors exhibited significantly higher proportions of total  
466 PBMCs at baseline compared to short-term survivors, which aligns with studies on PD-  
467 1/PD-L1 checkpoint blockade in lung cancer and melanoma demonstrating significant  
468 association between lower baseline neutrophil-to-lymphocyte ratios and improved  
469 progression-free and overall survival [31,32]. Correspondingly, patient P4, who exhibited  
470 the highest relative abundance of lymphocytes at baseline among all patients (figure  
471 2D), was the sole responder in the trial and demonstrated the longest survival. This data

472 suggests that EOC patients possessing an immune system more effectively primed for  
473 adaptive response may derive more consistent benefit from immunotherapy.

474 We observed a significant expansion of the CD14<sup>+</sup>CD16<sup>-</sup> myeloid cell compartment over  
475 the course of the first four treatment cycles. This expansion was initially driven by an  
476 increased abundance of HLA-DR<sup>+hi</sup> classical monocytes in the total cohort, and further  
477 sustained by an elevated frequency of HLA-DR<sup>-lo</sup> M-MDSCs in rapid progressors. This  
478 indicates a shift of the CD14<sup>+</sup>CD16<sup>-</sup> myeloid compartment towards a more  
479 immunosuppressive phenotype. Therefore, a sudden increase in the proportions of M-  
480 MDSCs in the peripheral blood of EOC patients treated with anti-CD73/PD-L1  
481 immunotherapy may serve as a potential biomarker of disease progression. Accordingly,  
482 higher HLA-DR expression on cells within the CD14<sup>+</sup>CD16<sup>-</sup> myeloid cell compartment  
483 has been positively associated with improved response to oleclumab [21] and  
484 immunotherapy targeting the PD-1/PD-L1 pathway [33]. Furthermore, cancer  
485 immunotherapy trials have consistently demonstrated that elevated MDSC abundance is  
486 associated with worse outcome in EOC [34], and various other cancers [35-37]. Growth  
487 factors and proinflammatory cytokines produced by cancer cells chronically stimulate  
488 myeloid progenitors, driving their differentiation towards M-MDSCs. Similarly, tumor-  
489 derived factors can induce the reprogramming of classical monocytes already present in  
490 peripheral blood towards M-MDSCs [38]. This expanded population of CD14<sup>+</sup>CD16<sup>-</sup>  
491 myeloid cells, likely representing precursors to tumor-associated macrophages, can be  
492 recruited to ovarian tumors, resulting in enhanced immunosuppression [34]. We  
493 hypothesize that EOC's concurrent utilization of a multitude of immunosuppressive  
494 mechanisms allows it to adapt and effectively resist targeted immunotherapy through

495 enhancement of immunosuppression mechanisms not currently affected by treatment.  
496 Such adaptation may be addressed by modifications or additions to the existing  
497 therapeutic approach. In line with this notion, MDSC-targeting agents have been  
498 preclinically and clinically evaluated in EOC with promising beneficial effect, also in  
499 combination with other immunotherapeutic approaches [34,39].

500 Our analysis showed a significant decline in the frequencies of  $T_{CM}$  cells in the  
501 peripheral blood of rapid progressors. Such a decline may have occurred as a  
502 consequence of the evolving immunosuppression in the underlying cancer. This  
503 hypothesis is supported by the observation that the  $T_{CM}$ -cell decline coincides with a  
504 substantial increase in peripheral M-MDSCs in these patients.  $T_{CM}$ -cell homeostasis may  
505 have been disrupted by the collective inhibition of the activation and differentiation of  
506 effector T cells into  $T_{CM}$  cells, and the inhibition of the reactivation and proliferation of  
507 tumor-proximal  $T_{CM}$  cells through an adaptive increase in adenosine generation. This  
508 effect may have been mediated by upregulation or induction of CD39/CD73 expression  
509 on tumor-recruited MDSCs [40], creating what is known as a “purinergic halo” [41]. The  
510 role of adenosine in driving the contraction of the  $T_{CM}$  subset is further supported the  
511 study of Mastelic-Gavillet et al., which showed that  $T_{CM}$  cells are especially vulnerable to  
512 adenosine-mediated dysfunction due to their high expression of the A2A receptor [30].

513 A novel observation of this study was the significant increase of PD-L1 on circulating T  
514 cells over time during administration of an anti-PD-L1 ICI. Research on other solid  
515 cancers has identified intratumoral PD-L1<sup>+</sup>CD8<sup>+</sup> T cells as drivers of T-cell exhaustion  
516 via the PD-L1/PD-1 axis, and as promoters of M2 macrophage polarization [42,43].  
517 Given that PD-L1 upregulation on T cells occurs following activation, we postulate that



518 the observed longitudinal upregulation of PD-L1 on circulating T cells in patients with  
519 EOC receiving oleclumab/durvalumab is a consequence of rapidly induced and  
520 progressively mutual exhaustion of activated T-cells.

521 Interestingly, we did not observe any significant longitudinal changes or inter-group  
522 differences in the expression of markers associated with adenosinergic signaling (CD39,  
523 CD73, p-S6, and p-CREB). This contradicts previous findings that documented  
524 oleclumab-induced inhibition and internalization of CD73 on CD4<sup>+</sup> and CD8<sup>+</sup> T cells [44].  
525 The stability of adenosinergic signaling observed in our study may be attributable to  
526 compensatory upregulation of CD73 expression, which possibly counteracted the  
527 expected oleclumab-mediated internalization.

528 Our study demonstrates a significant positive correlation between baseline CD73  
529 expression across various leukocyte subsets and PFS duration. This contradicts the  
530 prevailing view that CD73 expression in cancer generally correlates with poorer  
531 treatment outcome [45]. A limited number of studies have investigated CD73 expression  
532 in EOC [18,46], and ours is the first to link baseline CD73 expression with outcome in  
533 CD73-targeting cancer therapy. Although the positive correlation between baseline  
534 CD73 expression and PFS duration was observed for a range of leukocyte subsets,  
535 nearly all T-cell subsets are present in this set and represent a majority of the significant  
536 results. Thus, elevated baseline CD73 expression on peripheral blood T cells may serve  
537 as a predictive marker of longer PFS in patients with EOC set to undergo anti-CD73  
538 immunotherapy. We hypothesize that patients with higher baseline CD73 expression  
539 may have had tumors more heavily dependent on adenosinergic signaling for immune  
540 evasion, potentially enhancing the effectiveness of anti-CD73 treatment. Nonetheless,

541 this advantage appears to be temporary, as all patients ultimately experienced  
542 progression. This development may be attributed to the inherent immunosuppressive  
543 adaptability of EOC, as evident by the observed expansion of M-MDSCs and  
544 upregulation of PD-L1 in T cells.

545 In addition to the observed positive correlation between CD73 and longer PFS, our  
546 observation of a positive correlation between baseline IDO1 expression and longer PFS  
547 during EOC immunotherapy is in alignment with previous reports [47,48]. Although IDO1  
548 is generally viewed as a contributor to immunosuppression, our findings may be  
549 explained by its role in upregulating PD-L1 through the activation of the aryl hydrocarbon  
550 receptor by IDO1-generated tryptophan catabolites, as observed in solid tumors [49] and  
551 murine models of EOC [50]. Consequently, higher IDO1 expression in specific cell  
552 subsets could lead to increased PD-L1 expression on the same cells, potentially  
553 enhancing their susceptibility to durvalumab. Indeed, consistent with the study by  
554 Fujiwara et al. [47], our data also demonstrated a positive correlation between IDO1 and  
555 PD-L1 expression in leukocytes (online supplemental table S4). This correlation was  
556 significant and robust in subsets that showed the strongest associations between PD-L1  
557 expression and PFS duration, namely, classical monocytes, M-MDSCs, and CD141<sup>+</sup>  
558 myeloid dendritic cells. Therefore, IDO1 expression in the peripheral blood myeloid  
559 compartment may serve as a potential biomarker for the efficacy of EOC immunotherapy  
560 targeting PD-L1. Despite strong correlation coefficients and significant p-values, the  
561 validity of correlations between PD-L1 and PFS duration was limited by a low goodness-  
562 of-fit parameter, likely due to the small sample size. Therefore, a larger study is needed

563 to more definitively establish baseline PD-L1 expression in peripheral blood leukocytes  
564 as a predictive biomarker for EOC immunotherapy utilizing anti-PD-L1 ICIs.

565 This study examined sequentially sampled peripheral blood. An advantage of using  
566 blood samples, as opposed to tumor tissue biopsies, is that the information provided is  
567 not limited to a specific anatomical location. This is particularly valuable in cases of  
568 metastatic disease and offers a more comprehensive view of the patient's overall  
569 condition. Additionally, blood sampling is more flexible, clinically accessible, cost-  
570 effective, less invasive, and avoids the need for radiological imaging or surgical  
571 procedures for sample acquisition. However, the implementation of our 40-marker panel  
572 in the clinical setting is constrained by the high costs and complexity of the CyTOF  
573 methodology. Therefore, a more focused set of markers or leukocyte subsets, as  
574 suggested in this study, could represent a biomarker panel analyzable via methods  
575 already utilized in routine clinical diagnostics, such as flow cytometry or ELISA.

576 Overall, the small number of patient samples in this study affects the statistical power  
577 and limits the generalizability of the results. However, the diversity within the patient  
578 population - encompassing a wide range of ages, disease stages, and prior treatments -  
579 adds to the robustness and relevance of our observations for a broader spectrum of  
580 patients with relapsed EOC undergoing immunotherapy. Furthermore, the use of single-  
581 cell suspension CyTOF allowed us to generate extensive data from the limited sample  
582 set. Coupled with high-dimensional unsupervised clustering algorithms, this approach  
583 provided numerous insights and perspectives, strengthening the conclusions of the  
584 study.

585 Another limitation of this study is the absence of control arms comprising patients  
586 treated with either oleclumab or durvalumab alone [15]. Such control groups would have  
587 provided data integral for the conclusive attribution of the observed differences in  
588 leukocyte abundances and states to the effects of a certain immunotherapeutic. In  
589 addition, patients had undergone multiple rounds of cancer therapy prior to inclusion,  
590 which may have exerted developmental pressure on the tumors and potentially  
591 influenced response to oleclumab/durvalumab treatment. Although an expanded trial  
592 including single-agent arms and newly diagnosed EOC patients would help clarify the  
593 individual contribution of each compound to treatment outcome, the limited clinical  
594 activity of the oleclumab/durvalumab combination in the NSGO-OV-UMB1 trial [15]  
595 makes it difficult and ethically questionable to initiate such a randomized phase II or III  
596 trial.

597 In conclusion, our findings offer comprehensive insights into the effects of combination  
598 oleclumab/durvalumab immunotherapy on the peripheral blood leukocytes of relapsed  
599 EOC patients and elucidate potential immunosuppressive mechanisms employed by  
600 EOC to counteract the effects of immunotherapy. We propose blood-based biomarkers  
601 for better patient selection and non-invasive monitoring of disease progression; however,  
602 validation in larger patient cohorts is necessary.

603

## 604 **DECLARATIONS**

## 605 **Author affiliations**

606 <sup>1</sup>Centre for Cancer Biomarkers CCBIO, Department of Clinical Science, University of  
607 Bergen, Bergen, Norway

608 <sup>2</sup>Department of Obstetrics and Gynecology, Haukeland University Hospital, Bergen,  
609 Norway

610 <sup>3</sup>Department of Obstetrics and Gynecology and Tays Cancer Centre, Tampere University  
611 Hospital, Tampere, Finland

612 <sup>4</sup>Nordic Society of Gynaecological Oncology – Clinical Trial Unit (NSGO-CTU), Tampere,  
613 Finland

614 <sup>5</sup>Nordic Society of Gynaecological Oncology – Clinical Trial Unit (NSGO-CTU),  
615 Copenhagen, Denmark

616 <sup>6</sup>Department of Health Registry Research and Development, Norwegian Institute of  
617 Public Health, Oslo, Norway

618 <sup>7</sup>Kinn Therapeutics AS, Bergen, Norway

619 <sup>8</sup>Centre for Pharmacy, Department of Clinical Science, University of Bergen, Bergen,  
620 Norway

621 <sup>9</sup>Department of Internal Medicine, Hematology Section, Haukeland University Hospital,  
622 Bergen, Norway

623 <sup>10</sup>Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland

624 <sup>11</sup>Department of Oncology, Rigshospitalet, Copenhagen University Hospital,  
625 Copenhagen, Denmark

626

627 **Acknowledgements** We thank the patients for their consent and participation in  
628 the study. We thank Brith Bergum and Jørn Skavland at the Flow Cytometry Core

629 Facility of the University of Bergen for providing support for our mass cytometry work.

630 We acknowledge BioRender.com as the platform used to create the figures in this  
631 manuscript.

632

633 **Authors' Contributions** Study conceptualization and design: LT, MRM, LB. Clinical  
634 sample collection: AA, JM, KM, KSP, MRM, LB. Clinical database administration: RdPC,  
635 KM, KSP. Data generation: LT, CEW. Data analysis and statistics: LT. Data interpretation:  
636 LT, KK, LCVT, EMC, LB. Manuscript writing and editing: LT, KK, LCVT, LB. Manuscript  
637 review: All authors. Project administration: LT, KM, KSP, MRM, LB. Funding acquisition:  
638 MRM, LB. Guarantors: MRM, LB.

639

640 **Funding** This work was supported by grants from the Western Norway Regional  
641 Health Authority (Project No. 28543) and the Research Council of Norway through its  
642 Centres of Excellence funding scheme (Project No. 223250). AstraZeneca provided a  
643 grant to partially fund the trial and the investigational medicinal products (oleclumab and  
644 durvalumab). The funding sources were not involved in the study design, the collection  
645 of data, or the analysis and interpretation of data.

646

647 **Competing interests** AA has participated on the advisory boards of  
648 GlaxoSmithKline and Merck Sharp and Dohme; RdPC is employed by and is a  
649 shareholder of Y-mAbs Pharmaceuticals; LCVT has received personal fees for lectures  
650 from Bayer and AstraZeneca, personal fee payments from Eisai for participating on an

651 expert board, and has received a grant related to a clinical trial from AstraZeneca; CEW  
652 has received financial support for conference attendance and travel expenses from  
653 Beckman Coulter Inc.; EMC is a shareholder of KinN Therapeutics AS; JM has received  
654 a honorarium for a lecture from Eisai; KM has received speakers' honoraria and  
655 received compensation for travel expenses from GlaxoSmithKline and AstraZeneca, has  
656 participated in a trial-specific safety review committee for Kancera AB, and is a deputy  
657 medical director for NSGO-CTU; MRM has received an institutional study grant and  
658 investigational medicinal product from AstraZeneca (no personal grants were received);  
659 LB has received honoraria for lectures from GlaxoSmithKline and Merck Sharp and  
660 Dohme, has received a research grant from AstraZeneca for a researcher-initiated trial,  
661 and has had leadership roles in Onkologisk Forum between 2018 and 2022 and in the  
662 NSGO and NSGO-CTU since 2021; LT, KK and KSP report no personal conflicts of  
663 interest.

664

665 **Data availability statement** Data are available from the corresponding author  
666 upon request.

667

668 **Ethics approval** The study protocol and use of patient material in this study was  
669 approved by the regional ethical committees or institutional review boards of the  
670 participating sites: The Scientific Ethics Committee for the Capital Region of Denmark  
671 (VEK) (approval no. H-17025483), The Regional Committee for Medical Research  
672 Ethics Western Norway (REK West) (approval no. 2018/580), and The Regional Ethics

673 Committee of the Expert Responsibility area of Tampere University Hospital (TAYS)  
674 (approval no. R18078M). The study was conducted in accordance with the good clinical  
675 practice guidelines and provisions of the Declaration of Helsinki, as well as according to  
676 all local regulations.

677  
678 **Patient consent** All patients provided written informed consent for use of the clinical  
679 information and biological materials.

680  
681 **Provenance and peer review** Not commissioned; externally peer reviewed.

682  
683 **Supplemental material** This content has been supplied by the author(s). It has not  
684 been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-  
685 reviewed. Any opinions or recommendations discussed are solely those of the author(s)  
686 and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from  
687 any reliance placed on the content. Where the content includes any translated material,  
688 BMJ does not warrant the accuracy and reliability of the translations (including but not  
689 limited to local regulations, clinical guidelines, terminology, drug names and drug  
690 dosages), and is not responsible for any error and/or omissions arising from translation  
691 and adaptation or otherwise.

692



693 **Open access** This is an open access article distributed in accordance with the  
694 Creative Commons Attribution (CC BY 4.0) license, which permits others to copy,  
695 redistribute, remix, transform and build upon this work for any purpose, provided the  
696 original work is properly cited, appropriate credit is given, any changes made are  
697 indicated. See: <https://creativecommons.org/licenses/by/4.0/>.

698

### 699 **ORCID IDs**

700 Luka Tandaric <https://orcid.org/0009-0009-1431-2586>

701 Annika Auranen <https://orcid.org/0000-0002-9678-4684>

702 Katrin Kleinmanns <https://orcid.org/0000-0003-1402-8568>

703 René DePont Christensen <https://orcid.org/0009-0007-0919-236X>

704 Liv Cecilie Vestrheim Thomsen <https://orcid.org/0000-0002-6787-8518>

705 Cara Ellen Wogsland <https://orcid.org/0000-0003-1797-7902>

706 Emmet McCormack <https://orcid.org/0000-0002-7621-4625>

707 Johanna Mäenpää <https://orcid.org/0000-0003-0486-6912>

708 Kristine Madsen <https://orcid.org/0009-0004-4552-1931>

709 Karen Stampe Petersson <https://orcid.org/0009-0008-9757-1913>

710 Mansoor Raza Mirza <https://orcid.org/0000-0002-8085-1010>

711 Line Bjørge <https://orcid.org/0000-0002-0240-2770>

712

## 713 REFERENCES

- 714 [1] L. Kuroki, S.R. Guntupalli. Treatment of epithelial ovarian cancer. *BMJ* 371 (2020)  
715 m3773. DOI:10.1136/bmj.m3773
- 716 [2] A. Gadducci, S. Cosio. Randomized Clinical Trials and Real World Prospective  
717 Observational Studies on Bevacizumab, PARP Inhibitors, and Immune Checkpoint  
718 Inhibitors in the First-Line Treatment of Advanced Ovarian Carcinoma: A Critical Review.  
719 *Anticancer Res* 41(10) (2021) 4673-4685. DOI:10.21873/anticancer.15281
- 720 [3] S.L. Cooke, J.D. Brenton. Evolution of platinum resistance in high-grade serous  
721 ovarian cancer. *Lancet Oncol* 12(12) (2011) 1169-1174. DOI:10.1016/S1470-  
722 2045(11)70123-1
- 723 [4] M. McMullen, A. Madariaga, S. Lheureux. New approaches for targeting platinum-  
724 resistant ovarian cancer. *Semin Cancer Biol* 77 (2021) 167-181.  
725 DOI:10.1016/j.semcancer.2020.08.013
- 726 [5] H.E. Marei, A. Hasan, G. Pozzoli, et al., Cancer immunotherapy with immune  
727 checkpoint inhibitors (ICIs): potential, mechanisms of resistance, and strategies for  
728 reinvigorating T cell responsiveness when resistance is acquired. *Cancer Cell Int* 23(1)  
729 (2023) 64. DOI:10.1186/s12935-023-02902-0
- 730 [6] L. Zhang, J.R. Conejo-Garcia, D. Katsaros, et al., Intratumoral T cells, recurrence,  
731 and survival in epithelial ovarian cancer. *N Engl J Med* 348(3) (2003) 203-213.  
732 DOI:10.1056/NEJMoa020177
- 733 [7] T.J. Curiel, G. Coukos, L. Zou, et al., Specific recruitment of regulatory T cells in  
734 ovarian carcinoma fosters immune privilege and predicts reduced survival. *Nat Med*  
735 10(9) (2004) 942-949. DOI:10.1038/nm1093
- 736 [8] A. Varga, S. Piha-Paul, P.A. Ott, et al., Pembrolizumab in patients with  
737 programmed death ligand 1-positive advanced ovarian cancer: Analysis of KEYNOTE-  
738 028. *Gynecol Oncol* 152(2) (2019) 243-250. DOI:10.1016/j.ygyno.2018.11.017
- 739 [9] B.A. Maiorano, M.F.P. Maiorano, D. Lorusso, et al., Ovarian Cancer in the Era of  
740 Immune Checkpoint Inhibitors: State of the Art and Future Perspectives. *Cancers*  
741 (Basel) 13(17) (2021). DOI:10.3390/cancers13174438
- 742 [10] C. Yang, B.R. Xia, Z.C. Zhang, et al., Immunotherapy for Ovarian Cancer:  
743 Adjuvant, Combination, and Neoadjuvant. *Front Immunol* 11 (2020) 577869.  
744 DOI:10.3389/fimmu.2020.577869

- 745 [11] A. Martinez, J.P. Delord, M. Ayyoub, et al., Preclinical and Clinical  
746 Immunotherapeutic Strategies in Epithelial Ovarian Cancer. *Cancers (Basel)* 12(7)  
747 (2020). DOI:10.3390/cancers12071761
- 748 [12] B. Allard, S. Pommey, M.J. Smyth, et al., Targeting CD73 enhances the antitumor  
749 activity of anti-PD-1 and anti-CTLA-4 mAbs. *Clin Cancer Res* 19(20) (2013) 5626-5635.  
750 DOI:10.1158/1078-0432.CCR-13-0545
- 751 [13] F. Polesso, A.D. Weinberg, A.E. Moran. Late-Stage Tumor Regression after PD-  
752 L1 Blockade Plus a Concurrent OX40 Agonist. *Cancer Immunol Res* 7(2) (2019) 269-  
753 281. DOI:10.1158/2326-6066.CIR-18-0222
- 754 [14] W.L. Redmond, S.N. Linch, M.J. Kasiewicz. Combined targeting of costimulatory  
755 (OX40) and coinhibitory (CTLA-4) pathways elicits potent effector T cells capable of  
756 driving robust antitumor immunity. *Cancer Immunol Res* 2(2) (2014) 142-153.  
757 DOI:10.1158/2326-6066.CIR-13-0031-T
- 758 [15] M.R. Mirza, L. Tandaric, J.R. Henriksen, et al., NSGO-OV-UMB1/ENGOT-OV30:  
759 A phase II study of durvalumab in combination with the anti-CD73 monoclonal antibody  
760 Oleclumab in patients with relapsed ovarian cancer. *Gynecol Oncol* 188 (2024) 103-110.  
761 DOI:10.1016/j.ygyno.2024.06.017
- 762 [16] M. Uhlen, L. Fagerberg, B.M. Hallstrom, et al., Proteomics. Tissue-based map of  
763 the human proteome. *Science* 347(6220) (2015) 1260419.  
764 DOI:10.1126/science.1260419
- 765 [17] M. Uhlen, C. Zhang, S. Lee, et al., A pathology atlas of the human cancer  
766 transcriptome. *Science* 357(6352) (2017). DOI:10.1126/science.aan2507
- 767 [18] M. Turcotte, K. Spring, S. Pommey, et al., CD73 is associated with poor prognosis  
768 in high-grade serous ovarian cancer. *Cancer Res* 75(21) (2015) 4494-4503.  
769 DOI:10.1158/0008-5472.CAN-14-3569
- 770 [19] F. Ghiringhelli, M. Bruchard, F. Chalmin, et al., Production of adenosine by  
771 ectonucleotidases: a key factor in tumor immunoescape. *J Biomed Biotechnol* 2012  
772 (2012) 473712. DOI:10.1155/2012/473712
- 773 [20] S. Chen, D.A. Wainwright, J.D. Wu, et al., CD73: an emerging checkpoint for  
774 cancer immunotherapy. *Immunotherapy* 11(11) (2019) 983-997. DOI:10.2217/imt-2018-  
775 0200
- 776 [21] C.M. Hay, E. Sult, Q. Huang, et al., Targeting CD73 in the tumor  
777 microenvironment with MEDI9447. *Oncoimmunology* 5(8) (2016) e1208875.  
778 DOI:10.1080/2162402X.2016.1208875
- 779 [22] M. Moller, V. Orth, V. Umansky, et al., Myeloid-derived suppressor cells in  
780 peripheral blood as predictive biomarkers in patients with solid tumors undergoing

- 781 immune checkpoint therapy: systematic review and meta-analysis. *Front Immunol* 15  
782 (2024) 1403771. DOI:10.3389/fimmu.2024.1403771
- 783 [23] K. Okla, A. Czerwonka, A. Wawruszak, et al., Clinical Relevance and  
784 Immunosuppressive Pattern of Circulating and Infiltrating Subsets of Myeloid-Derived  
785 Suppressor Cells (MDSCs) in Epithelial Ovarian Cancer. *Front Immunol* 10 (2019) 691.  
786 DOI:10.3389/fimmu.2019.00691
- 787 [24] E.R. Zunder, R. Finck, G.K. Behbehani, et al., Palladium-based mass tag cell  
788 barcoding with a doublet-filtering scheme and single-cell deconvolution algorithm. *Nat*  
789 *Protoc* 10(2) (2015) 316-333. DOI:10.1038/nprot.2015.020
- 790 [25] S. Granjeaud. cytoBatchNorm. 2022; <https://github.com/i-cyto/cytoBatchNorm>.  
791 (Accessed: 01. Sep. 2024)
- 792 [26] S. Van Gassen, B. Callebaut, M.J. Van Helden, et al., FlowSOM: Using self-  
793 organizing maps for visualization and interpretation of cytometry data. *Cytometry A* 87(7)  
794 (2015) 636-645. DOI:10.1002/cyto.a.22625
- 795 [27] E. Becht, L. McInnes, J. Healy, et al., Dimensionality reduction for visualizing  
796 single-cell data using UMAP. *Nat Biotechnol* (2018). DOI:10.1038/nbt.4314
- 797 [28] H. Crowell, V. Zanutelli, S. Chevrier, et al. CATALYST: Cytometry dATa anALYSis  
798 Tools. R package version 1.28.0. 2024; <https://github.com/HelenaLC/CATALYST>.  
799 (Accessed: 01. Sep. 2024)
- 800 [29] L.M. Weber, M. Nowicka, C. Sonesson, et al., diffcyt: Differential discovery in high-  
801 dimensional cytometry via high-resolution clustering. *Commun Biol* 2 (2019) 183.  
802 DOI:10.1038/s42003-019-0415-5
- 803 [30] B. Mastelic-Gavillet, B. Navarro Rodrigo, L. Decombaz, et al., Adenosine  
804 mediates functional and metabolic suppression of peripheral and tumor-infiltrating  
805 CD8(+) T cells. *J Immunother Cancer* 7(1) (2019) 257. DOI:10.1186/s40425-019-0719-5
- 806 [31] Y. Li, Z. Zhang, Y. Hu, et al., Pretreatment Neutrophil-to-Lymphocyte Ratio (NLR)  
807 May Predict the Outcomes of Advanced Non-small-cell Lung Cancer (NSCLC) Patients  
808 Treated With Immune Checkpoint Inhibitors (ICIs). *Front Oncol* 10 (2020) 654.  
809 DOI:10.3389/fonc.2020.00654
- 810 [32] J.T. Cohen, T.J. Miner, M.P. Vezeridis. Is the neutrophil-to-lymphocyte ratio a  
811 useful prognostic indicator in melanoma patients? *Melanoma Manag* 7(3) (2020)  
812 MMT47. DOI:10.2217/mmt-2020-0006
- 813 [33] C. Krieg, M. Nowicka, S. Guglietta, et al., High-dimensional single-cell analysis  
814 predicts response to anti-PD-1 immunotherapy. *Nat Med* 24(2) (2018) 144-153.  
815 DOI:10.1038/nm.4466

- 816 [34] K. Okla. Myeloid-Derived Suppressor Cells (MDSCs) in Ovarian Cancer-Looking  
817 Back and Forward. *Cells* 12(14) (2023). DOI:10.3390/cells12141912
- 818 [35] P. Kongsted, T.H. Borch, E. Ellebaek, et al., Dendritic cell vaccination in  
819 combination with docetaxel for patients with metastatic castration-resistant prostate  
820 cancer: A randomized phase II study. *Cytotherapy* 19(4) (2017) 500-513.  
821 DOI:10.1016/j.jcyt.2017.01.007
- 822 [36] C. Meyer, L. Cagnon, C.M. Costa-Nunes, et al., Frequencies of circulating MDSC  
823 correlate with clinical outcome of melanoma patients treated with ipilimumab. *Cancer*  
824 *Immunol Immunother* 63(3) (2014) 247-257. DOI:10.1007/s00262-013-1508-5
- 825 [37] G. Enblad, H. Karlsson, G. Gammelgard, et al., A Phase I/IIa Trial Using CD19-  
826 Targeted Third-Generation CAR T Cells for Lymphoma and Leukemia. *Clin Cancer Res*  
827 24(24) (2018) 6185-6194. DOI:10.1158/1078-0432.CCR-18-0426
- 828 [38] K. Li, H. Shi, B. Zhang, et al., Myeloid-derived suppressor cells as  
829 immunosuppressive regulators and therapeutic targets in cancer. *Signal Transduct*  
830 *Target Ther* 6(1) (2021) 362. DOI:10.1038/s41392-021-00670-9
- 831 [39] Y. Berckmans, Y. Hoffert, A. Vankerckhoven, et al., Drug Repurposing for  
832 Targeting Myeloid-Derived Suppressor-Cell-Generated Immunosuppression in Ovarian  
833 Cancer: A Literature Review of Potential Candidates. *Pharmaceutics* 15(7) (2023).  
834 DOI:10.3390/pharmaceutics15071792
- 835 [40] J. Li, L. Wang, X. Chen, et al., CD39/CD73 upregulation on myeloid-derived  
836 suppressor cells via TGF-beta-mTOR-HIF-1 signaling in patients with non-small cell lung  
837 cancer. *Oncoimmunology* 6(6) (2017) e1320011. DOI:10.1080/2162402X.2017.1320011
- 838 [41] L. Antonioli, P. Pacher, E.S. Vizi, et al., CD39 and CD73 in immunity and  
839 inflammation. *Trends Mol Med* 19(6) (2013) 355-367.  
840 DOI:10.1016/j.molmed.2013.03.005
- 841 [42] B. Diskin, S. Adam, M.F. Cassini, et al., PD-L1 engagement on T cells promotes  
842 self-tolerance and suppression of neighboring macrophages and effector T cells in  
843 cancer. *Nat Immunol* 21(4) (2020) 442-454. DOI:10.1038/s41590-020-0620-x
- 844 [43] Y. Zheng, L. Han, Z. Chen, et al., PD-L1(+)CD8(+) T cells enrichment in lung  
845 cancer exerted regulatory function and tumor-promoting tolerance. *iScience* 25(2) (2022)  
846 103785. DOI:10.1016/j.isci.2022.103785
- 847 [44] J. Bendell, P. LoRusso, M. Overman, et al., First-in-human study of oleclumab, a  
848 potent, selective anti-CD73 monoclonal antibody, alone or in combination with  
849 durvalumab in patients with advanced solid tumors. *Cancer Immunol Immunother* 72(7)  
850 (2023) 2443-2458. DOI:10.1007/s00262-023-03430-6
- 851 [45] N. Bach, R. Winzer, E. Tolosa, et al., The Clinical Significance of CD73 in Cancer.  
852 *Int J Mol Sci* 24(14) (2023). DOI:10.3390/ijms241411759

853 [46] H.K. Oh, J.I. Sin, J. Choi, et al., Overexpression of CD73 in epithelial ovarian  
854 carcinoma is associated with better prognosis, lower stage, better differentiation and  
855 lower regulatory T cell infiltration. *J Gynecol Oncol* 23(4) (2012) 274-281.  
856 DOI:10.3802/jgo.2012.23.4.274

857 [47] Y. Fujiwara, S. Kato, D. Nishizaki, et al., High indoleamine 2,3-dioxygenase  
858 transcript levels predict better outcome after front-line cancer immunotherapy. *iScience*  
859 27(4) (2024) 109632. DOI:10.1016/j.isci.2024.109632

860 [48] I. Hoffmann, M.P. Dragomir, N. Monje, et al., Increased expression of IDO1 is  
861 associated with improved survival and increased number of TILs in patients with high-  
862 grade serous ovarian cancer. *Neoplasia* 44 (2023) 100934.  
863 DOI:10.1016/j.neo.2023.100934

864 [49] J.E. Kenison, Z. Wang, K. Yang, et al., The aryl hydrocarbon receptor suppresses  
865 immunity to oral squamous cell carcinoma through immune checkpoint regulation. *Proc*  
866 *Natl Acad Sci U S A* 118(19) (2021). DOI:10.1073/pnas.2012692118

867 [50] A. Amobi-McCloud, R. Muthuswamy, S. Battaglia, et al., IDO1 Expression in  
868 Ovarian Cancer Induces PD-1 in T Cells via Aryl Hydrocarbon Receptor Activation. *Front*  
869 *Immunol* 12 (2021) 678999. DOI:10.3389/fimmu.2021.678999

870

## 871 **FIGURE AND TABLE CAPTIONS**

872 **Figure 1** Trial overview, sample collection and processing. (A) Schema of the  
873 patient disposition and immunotherapy administration schedule of the NSGO-OV-  
874 UMB1/ENGOT-OV30 trial. One treatment cycle had a duration of four weeks. (B) Blood  
875 sample acquisition and processing workflow (full protocol provided in the online  
876 supplemental appendix). (C) Swimmer plot illustrating the duration of treatment and  
877 observation for each patient included in this study, as well as blood sampling timepoints.  
878 IV – intravenous

879

880 **Online supplemental table S1** The 40-marker mass cytometry panel used for  
881 immunophenotyping in this study. \*Titrated on both non-stimulated leukocytes and  
882 stimulated PBMCs; †Titrated on stimulated PBMCs; ‡Intracellular target; §Conjugated in-  
883 house

884  
885 **Online supplemental figure S1** Cleanup gating workflow used for the refinement of  
886 the raw cytometry by time-of-flight (CyTOF) data into intact single cells (singlets).

887  
888 **Figure 2** Formation and overall view of the study dataset. (A) Heatmap of the  
889 normalized median expression of the 13 markers (rows) used for the clustering of total  
890 leukocytes. Each column represents a cluster. Appropriateness of leukocyte subset  
891 assignment\* was confirmed by unsupervised hierarchical clustering (visualized above  
892 heatmap). (B) Heatmap of the normalized median expression of the 22 markers (rows)  
893 used for the clustering of PBMCs. Each column represents a leukocyte subset. Subset  
894 assignment\* was performed and validated in the same manner as for the total leukocyte  
895 clusters. (C) UMAP projection of an aggregated sample of PBMCs, consisting of an  
896 equal number of cells sampled from each blood sample. Each cell is colored by subset  
897 assignment\*. (D) Overview of the leukocyte (upper stacked bar plots) and PBMC (lower  
898 stacked bar plots) composition of all blood samples (detailed composition of each  
899 sample is given in online supplemental table S2). \*Leukocyte subset assignment  
900 coloring is consistent throughout figure 2. TCRgd - gamma-delta T-cell receptor

901

902 **Table 1** Characteristics of the included patients.

903

904 **Figure 3** Significant differences, changes, and trends in the relative abundances of  
905 leukocyte populations. (A) Comparison of the relative baseline abundances of  
906 granulocytes and total PBMCs between survival duration groups (short-term survival is  
907 defined as observed survival of at most 16 weeks since the start of treatment; long-term  
908 survival is defined as observed survival of more than 16 weeks since the start of  
909 treatment). Symbols representing each patient are consistent throughout all figures. (B)  
910 UMAP projections of aggregated baseline samples of total leukocytes stratified by  
911 survival duration group. Both projections consist of the same number of cells. The  
912 significant difference in the density of the total PBMC subset between groups is  
913 accented with a dashed blue outline. (C) Changes in the relative abundances of  
914 classical monocytes and monocytic myeloid-derived suppressor cells (M-MDSCs) during  
915 treatment in the group of long-term survivors (n=7). The two PBMC subsets composed  
916 of CD14<sup>+</sup>CD16<sup>-</sup> myeloid cells (Monocytes - Classical and M-MDSCs), are shown  
917 separately in the left and middle panel. The level of HLA-DR expression forms the basis  
918 for the separation of classical monocytes (HLA-DR<sup>+/hi</sup>) from M-MDSCs (HLA-DR<sup>-/lo</sup>)  
919 (online supplemental figure S2). In the right panel, the classical monocyte and M-MDSC  
920 subsets were merged to illustrate the significant and continued increase of the  
921 abundance of CD14<sup>+</sup>CD16<sup>-</sup> myeloid cells during treatment. (D) UMAP projections of  
922 aggregated PBMC samples from the long-term survivors (n=7), stratified by treatment



923 timepoint. Cells of the “Monocytes-Classical” and “M-MDSCs” subsets are delineated  
924 with a blue outline. (E) Changes in the relative abundances of M-MDSCs during  
925 treatment. Patients were stratified into rapid progressors (progression confirmed after at  
926 most 16 weeks since the start of treatment) and slow progressors (progression  
927 confirmed after more than 16 weeks since the start of treatment). (F) Changes in the  
928 relative abundances of central memory (CM) T-cell subsets during treatment. Patients  
929 were stratified into rapid- and slow progressors. (G) Comparison of the relative  
930 abundances of M-MDSCs in samples collected at blood sampling timepoints  
931 immediately before and after confirmation of disease progression. ns - not significant; \* -  
932  $p_{\text{adj}} < 0.05$ ; \*\*\* -  $p_{\text{adj}} < 0.001$

933

934 **Online supplemental figure S2** Determination of the cutoff of HLA-DR expression for  
935 the separation of classical monocytes and myeloid monocyte-derived suppressor cells.  
936 (A) The subset of naïve CD4<sup>+</sup> T cells was used as a negative control for HLA-DR  
937 expression. (B) The subset of naïve B cells was used as a positive control for HLA-DR  
938 expression. (C) The cutoff of HLA-DR expression for the separation of the cells of the  
939 CD14<sup>+</sup>CD16<sup>-</sup> myeloid cell subset was set according to the optimal expression cutoffs in  
940 the negative and positive control subsets.

941

942 **Online supplemental table S2** Detailed sample composition data.

943

944 **Figure 4** Significant changes in cell state marker expression during treatment. (A)  
945 Heatmaps of the top significant differences in the relative state marker expression in  
946 long-term survivor samples taken at baseline (n=7) (left half of the heatmaps) and after  
947 either two (right half of left heatmap) or four treatment cycles (right half of right  
948 heatmap). Each row of the heatmap is labeled with the combination of marker (left) and  
949 subset (right, in brackets) it represents, sorted from top to bottom based on increasing p-  
950 value. (B) Median arcSinh(5)-transformed expression of PD-L1 over time for all T-cell  
951 subsets in the long-term survivor (n=7) samples. The trendline was calculated using  
952 simple linear regression. \* -  $p_{adj} < 0.05$ ; CM - central memory; E - effector; EM - effector  
953 memory; GranB - granzyme B; logFC -  $\log_2$ (fold change); Mono - monocytes; N - naïve;  
954 NC - non-classical; NK-56 - CD56<sup>+++</sup> NK cells; NKT - NKT cells; ns - not significant; T-  
955 CD4 - CD4<sup>+</sup> T cells; T-CD8 - CD8<sup>+</sup> T cells; T-DN - CD4<sup>-</sup>CD8<sup>-</sup> (double-negative) T cells;  
956 Tgd - gamma-delta T cells

957

958 **Figure 5** Correlations between progression-free survival duration and either the  
959 relative leukocyte subset abundances or state marker expression levels at baseline for  
960 long-term survivors (n=7). (A) Heatmap showing correlation analysis results (online  
961 supplemental table S3). Pearson or Spearman correlation analysis was selected based  
962 on the normality of the dataset, assessed using the Shapiro-Wilk test. (B) Plots depicting  
963 significant correlations between transformed median CD73 expression at baseline and  
964 time to progression. Symbols representing each patient are consistent throughout Fig. 5.  
965 (C) Plots illustrating most significant correlations between transformed median IDO1  
966 expression at baseline and time to progression. |r| - absolute value of Pearson's

967 correlation coefficient;  $|\rho|$  - absolute value of Spearman's correlation coefficient; GranB -

968 granzyme B



969




970 **Online supplemental table S3** Full correlation testing results.


971


972 **Online supplemental table S4** Results of correlation testing between IDO1 and PD-

973 L1 expression at baseline.







**A****B**